Business Context and Reporting Period
Company: Palatin Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended December 31, 2006.
Business Overview: Palatin is a biopharmaceutical company focused on developing targeted, receptor-specific small molecule and peptide therapeutics, primarily based on melanocortin (MC) receptors. Key programs include bremelanotide (for sexual dysfunction, in collaboration with King Pharmaceuticals) and NeutroSpec (for infection imaging, suspended in collaboration with Mallinckrodt).
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2006 | Six Months Ended Dec 31, 2005 |
|---|---|---|
| Total Revenues | $8,678,211 | $9,730,916 |
| Net Loss | $(14,925,883) | $(13,479,228) |
| Net Loss Per Share (Basic/Diluted) | $(0.21) | $(0.24) |
| Operating Cash Flow | $(14,827,582) | $(9,025,589) |
| Cash and Cash Equivalents (Ending) | $13,673,924 | $16,763,421 |
| Total Assets | $24,669,392 | $40,047,287 (June 30, 2006) |
| Total Liabilities | $19,887,027 | $21,747,506 (June 30, 2006) |
| Accumulated Deficit | $(175,369,427) | $(160,443,544) (June 30, 2006) |
Revenue Composition: 98% of revenue for the six months ended Dec 31, 2006, was derived from the collaboration with King Pharmaceuticals. Royalty revenue from NeutroSpec was $0 due to the suspension of sales.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately $1.05 million (11%) compared to the prior year period. This was driven by the complete absence of royalty revenue from NeutroSpec (which contributed $1.5 million in the prior year) following the suspension of sales in December 2005. License and contract revenue increased slightly to $8.7 million from $8.2 million.
- Increased Operating Loss: Net loss increased by approximately $1.45 million. This was primarily due to higher Research and Development (R&D) expenses, which rose to $21.7 million from $18.7 million, driven by increased clinical study costs for bremelanotide.
- Cash Burn: Net cash used in operating activities increased significantly to $14.8 million from $9.0 million in the prior year period. Cash and cash equivalents decreased by approximately $14.7 million during the six-month period.
- Cost of Sales: Cost of product sales was $0 in the current period, compared to $2.0 million in the prior year, which represented a write-off of NeutroSpec inventory.
Guidance, Outlook, and Risks
Subsequent Event (AstraZeneca Agreement): On January 30, 2007, Palatin entered into an exclusive global licensing and research collaboration with AstraZeneca AB for MC receptor compounds targeting obesity and diabetes. The deal includes a $10 million upfront payment and potential milestone payments totaling up to $300 million.
Liquidity Outlook: Management believes current cash, cash equivalents, and available-for-sale investments ($16.0 million total as of Dec 31, 2006), combined with expected collaboration receipts, are sufficient to fund operations for at least the next twelve months. However, the company expects to incur additional losses in the future.
Risks and Contingencies:
- Development Risk: No assurance exists that product candidates will successfully complete clinical trials or obtain regulatory approval.
- Legal Proceedings: Competitive Technologies, Inc. (CTI) has initiated litigation regarding a settlement agreement. Palatin asserts counterclaims but cannot predict the outcome or estimate potential loss.
- Concentration Risk: Revenue is heavily concentrated with King Pharmaceuticals (98%). Accounts receivable are entirely due from Mallinckrodt.
- NeutroSpec Status: Sales and marketing of NeutroSpec remain suspended; future revenue depends on resumption of sales or new development activities.
Investor Verification Checklist
- AstraZeneca Deal Terms: Verify the specific milestones and conditions required to unlock the $300 million in potential payments from the January 2007 agreement.
- Cash Runway: Confirm the sufficiency of the $13.7 million cash balance against projected R&D spend for bremelanotide Phase 2B/3 trials and general operations.
- NeutroSpec Resolution: Monitor updates on the suspended NeutroSpec program and any potential resumption of sales or new indications.
- Legal Exposure: Track the status of the CTI litigation and arbitration to assess potential financial impact or distraction.
- Revenue Recognition: Review the amortization schedule for deferred revenue from King Pharmaceuticals, as changes in the estimated performance period could materially impact future quarterly revenue.